Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

Core Insights - Acumen Pharmaceuticals has initiated the open-label extension of its Phase 2 ALTITUDE-AD clinical trial for sabirnetug (ACU193), targeting early Alzheimer's disease [1][2][3] - The open-label extension allows participants from the placebo-controlled phase to receive sabirnetug for an additional 52 weeks, maintaining the same clinical measures and safety monitoring [2][3] - Sabirnetug is the first humanized monoclonal antibody to selectively target soluble amyloid beta oligomers (AβOs), which are implicated in the neurodegenerative process of Alzheimer's disease [3][5] - The company anticipates reporting topline results from the ALTITUDE-AD trial in late 2026 [4] Company Overview - Acumen Pharmaceuticals is focused on developing therapies targeting toxic soluble AβOs for Alzheimer's disease, with sabirnetug currently in Phase 2 trials following positive Phase 1 results [7][8] - The ALTITUDE-AD trial has enrolled 542 participants with early Alzheimer's disease across multiple sites in the U.S., Canada, EU, and the UK [6] - Sabirnetug has received Fast Track designation from the U.S. FDA for the treatment of early Alzheimer's disease [5]